<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268787</url>
  </required_header>
  <id_info>
    <org_study_id>QCR-10013</org_study_id>
    <nct_id>NCT01268787</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine</brief_title>
  <official_title>A Phase I, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine Administrated With Adjuvant AlPO4 in Health Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aims to evaluate the safety, reactogenicity and immunogenicity of EV71 vaccine
      at a 0.25ml or 0.5ml dose in health volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, prospective, randomized, open-label, two-center study. A total 60 healthy
      volunteers will be screened for baseline characteristic inclusion/exclusion criteria after
      providing a written informed consent. Eligible subjects will be recruited and equally
      randomized to either receive 2 doses of EV71 vaccine 0.25ml or 0.5ml. All subjects should be
      followed till Day 210.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint</measure>
    <time_frame>210 Days</time_frame>
    <description>The percentage, intensity and relationship to vaccination of local and systemic signs and symptoms at a 0.25ml and 0.5ml dose</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Enterovirus Infection</condition>
  <arm_group>
    <arm_group_label>EV 71 vaccine 5ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EV71 Vaccine 5ug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EV 71 vaccine 10ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EV71 vaccine 10ug</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine</intervention_name>
    <description>Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.</description>
    <arm_group_label>EV 71 vaccine 5ug</arm_group_label>
    <arm_group_label>EV 71 vaccine 10ug</arm_group_label>
    <other_name>EV71 vac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject who is free of obvious health problems

          -  Able and willing to comply with the study procedure adn give written informed consent

        Exclusion Criteria:

          -  Female who is pregnant/lactating or planning to be pregnant

          -  Body mass index(BMI) &gt; 35

          -  Oral temperature &gt; 37.5 Celsius at the time of planned vaccination

          -  Subject with any abnormal laboratory results at screening

          -  With a history of herpangina, hand-foot-mouth disease, acute hemorrhagic
             conjunctivitis or acute gastrointestinal illness associated with enterovirus infection
             in the past 3 months

          -  Has been diagnosed with neurological, pulmonary, cardiovascular, hematological,
             hepatic or renal disorder

          -  With a history of hypersensitivity to vaccine or allergic disease

          -  Use of any investigational/non-registered product within 30 days prior to vaccination

          -  Use of immunoglobulins or any blood products within 3 months prior to vaccination

          -  Chronic administration of immunosuppressants or other immunomodulators within 5 months
             prior to vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pele Chong, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>National Health Research Institutes, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chia-Chyi Liu, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>National Health Research Institutes, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C P Fung, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S M Hsieh, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Meidcal College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Shihlin District</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Zhongshan Distric</state>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2010</study_first_submitted>
  <study_first_submitted_qc>December 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2010</study_first_posted>
  <last_update_submitted>April 15, 2015</last_update_submitted>
  <last_update_submitted_qc>April 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

